Payment overview · 2025
General Payments
$494.24
22 reported records · 9 companies
Healthcare provider profile · identity verified
David C Stanford, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SUN CITY, CA · NPI 1568464923
Verified facts
What the public records show
CMS Open Payments records show David C Stanford, MD received $494.24 in general payments during 2025 across 22 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 39.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 337 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $195.97 | 39.6% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $64.66 | 13.1% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $50.82 | 10.3% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $39.54 | 8.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $37.20 | 7.5% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $36.48 | 7.4% | 2 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $34.87 | 7.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.88 | 3.6% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $16.82 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $494.24 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $246.79 | 10 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $45.42 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $39.54 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $37.20 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $36.48 | 2 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $34.87 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $23.20 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.88 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.88 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $16.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
71 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
337 | 58 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 640 | 169 |
| Atorvastatin Calcium | Atorvastatin Calcium | 638 | 181 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 517 | 89 |
| Lisinopril | Lisinopril | 455 | 135 |
| Alendronate Sodium | Alendronate Sodium | 395 | 126 |
| Amlodipine Besylate | Amlodipine Besylate | 390 | 120 |
| Metformin Hcl | Metformin Hcl | 382 | 114 |
| Furosemide | Furosemide | 348 | 112 |
| Gabapentin | Gabapentin | 346 | 95 |
| Ozempic | Semaglutide | 337 | 58 |
| Omeprazole | Omeprazole | 334 | 110 |
| Simvastatin | Simvastatin | 326 | 93 |
| Alprazolam | Alprazolam | 316 | 66 |
| Losartan Potassium | Losartan Potassium | 250 | 70 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 249 | 94 |
| Metoprolol Succinate | Metoprolol Succinate | 247 | 74 |
| Tamsulosin Hcl | Tamsulosin Hcl | 243 | 83 |
| Pravastatin Sodium | Pravastatin Sodium | 227 | 69 |
| Lorazepam | Lorazepam | 223 | 52 |
| Escitalopram Oxalate | Escitalopram Oxalate | 216 | 59 |
| Clopidogrel | Clopidogrel Bisulfate | 204 | 62 |
| Donepezil Hcl | Donepezil Hcl | 195 | 59 |
| Pantoprazole Sodium | Pantoprazole Sodium | 192 | 56 |
| Potassium Chloride | Potassium Chloride | 191 | 65 |
| Trazodone Hcl | Trazodone Hcl | 187 | 53 |
| Eliquis | Apixaban | 186 | 42 |
| Lovastatin | Lovastatin | 183 | 63 |
| Duloxetine Hcl | Duloxetine Hcl | 177 | 46 |
| Carvedilol | Carvedilol | 176 | 47 |
| Prednisone | Prednisone | 175 | 109 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 173 | 61 |
| Azithromycin | Azithromycin | 172 | 118 |
| Metoprolol Tartrate | Metoprolol Tartrate | 164 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 152 | 44 |
| Montelukast Sodium | Montelukast Sodium | 151 | 56 |
| Glimepiride | Glimepiride | 149 | 37 |
| Famotidine | Famotidine | 140 | 40 |
| Sertraline Hcl | Sertraline Hcl | 129 | 46 |
| Allopurinol | Allopurinol | 127 | 37 |
| Doxazosin Mesylate | Doxazosin Mesylate | 127 | 40 |
| Atenolol | Atenolol | 126 | 37 |
| Temazepam | Temazepam | 117 | 24 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 114 | 38 |
| Tramadol Hcl | Tramadol Hcl | 113 | 30 |
| Meloxicam | Meloxicam | 100 | 36 |
| Glipizide | Glipizide | 99 | 32 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 98 | 67 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 98 | 30 |
| Fenofibrate | Fenofibrate | 94 | 26 |
| Ibuprofen | Ibuprofen | 93 | 39 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 89 | 28 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 89 | 19 |
| Cephalexin | Cephalexin | 88 | 67 |
| Finasteride | Finasteride | 83 | 23 |
| Ezetimibe | Ezetimibe | 82 | 26 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 82 | 26 |
| Oxybutynin Chloride | Oxybutynin Chloride | 81 | 26 |
| Propranolol Hcl | Propranolol Hcl | 81 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 80 | 53 |
| Pregabalin | Pregabalin | 75 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 74 | 26 |
| Jardiance | Empagliflozin | 71 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 67 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 66 | 21 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 66 | 47 |
| Synthroid | Levothyroxine Sodium | 66 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 61 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 61 | 15 |
| Progesterone | Progesterone, Micronized | 61 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 60 | 48 |
| Fluticasone Propionate | Fluticasone Propionate | 59 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 59 | 19 |
| Valsartan | Valsartan | 59 | 17 |
| Benazepril Hcl | Benazepril Hcl | 58 | 20 |
| Fluconazole | Fluconazole | 57 | 34 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 57 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 54 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 52 | 11 |
| Clonidine Hcl | Clonidine Hcl | 51 | 18 |
| Estradiol (Twice Weekly) | Estradiol | 50 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 49 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 48 | 11 |
| Terbinafine Hcl | Terbinafine Hcl | 48 | 33 |
| Spironolactone | Spironolactone | 47 | 14 |
| Acyclovir | Acyclovir | 44 | 20 |
| Estradiol | Estradiol | 44 | 12 |
| Diazepam | Diazepam | 43 | suppressed |
| Methylprednisolone | Methylprednisolone | 43 | 37 |
| Memantine Hcl | Memantine Hcl | 42 | 11 |
| Amoxicillin | Amoxicillin | 41 | 35 |
| Celecoxib | Celecoxib | 41 | 21 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 41 | suppressed |
| Nifedipine Er | Nifedipine | 40 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 40 | 14 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 40 | suppressed |
| Baclofen | Baclofen | 39 | 11 |
| Cilostazol | Cilostazol | 38 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 38 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 37 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 37 | 11 |
| Clonazepam | Clonazepam | 36 | suppressed |
| Januvia | Sitagliptin Phosphate | 35 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 34 | 17 |
| Methenamine Hippurate | Methenamine Hippurate | 34 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | 14 |
| Myrbetriq | Mirabegron | 33 | 13 |
| Primidone | Primidone | 33 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 31 | 11 |
| Enalapril Maleate | Enalapril Maleate | 31 | suppressed |
| Ramipril | Ramipril | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Minoxidil | Minoxidil | 30 | suppressed |
| Nystatin | Nystatin | 30 | 11 |
| Risperidone | Risperidone | 30 | suppressed |
| Levofloxacin | Levofloxacin | 28 | 25 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 27 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Anastrozole | Anastrozole | 25 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 23 | suppressed |
| Bumetanide | Bumetanide | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Digoxin | Digoxin | 21 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | 12 |
| Meclizine Hcl | Meclizine Hcl | 21 | 13 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 21 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Lidocaine | Lidocaine | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | 15 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Dulera | Mometasone/Formoterol | 18 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 18 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 18 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 17 | suppressed |
| Pentoxifylline | Pentoxifylline | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Methimazole | Methimazole | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 13 |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 13 |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Fluocinonide | Fluocinonide | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Silodosin | Silodosin | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 11 | suppressed |
| Dalfampridine Er | Dalfampridine | 11 | suppressed |
| Dotti | Estradiol | 11 | suppressed |
| Klor-Con 10 | Potassium Chloride | 11 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 11 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Repaglinide | Repaglinide | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
| Vivelle-Dot | Estradiol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $494.24 · 22 records | Otsuka America Pharmaceutical, Inc. | Dexcom G6 Transmitter, FREESTYLE LIBRE 3, GEMTESA, MOUNJARO, OTEZLA, REPATHA, REXULTI, Tlando, Wegovy, ZEPBOUND | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error